ResMed Inc (RMD) KPIs and segments
Close on Nov 18, 2026Market cap $34.12BP/E 22.1Yield 0.99%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của ResMed · năm tài chính kết thúc June 30 (FY2026 ended June 30, 2026; Q1 FY2027 ended September 30, 2026)
Nhìn nhanh KPI của ResMed: 40 chỉ số vận hành, trong đó có Global Sleep & Breathing Health Revenue, Global Devices Revenue và Global Masks and Other Revenue, lấy từ 144 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của ResMed kết thúc June 30 (FY2026 ended June 30, 2026; Q1 FY2027 ended September 30, 2026) — Q1 FY27 = CQ3 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Devices3 | |||||||||||||
Global revenue($M) | 736 | 726 | 680 | 676 | 669 | 626 | 638 | 606 | |||||
U.S., Canada and Latin America($M) | 448 | 448 | 413 | 423 | 414 | 385 | 399 | 371 | |||||
Combined Europe, Asia and other markets($M) | 288 | 278 | 267 | 254 | 255 | 241 | 239 | 235 | |||||
Residential Care Software($M)1 | 155 | 172 | 171 | 167 | 166 | 167 | 161 | 156 | 157 | 152 | 148 | 145 | |
Global revenue($M) | 171 | 167 | 166 | 161 | 156 | 157 | 148 | 145 | |||||
Masks and other3 | |||||||||||||
Global revenue($M) | 525 | 530 | 489 | 454 | 456 | 442 | 411 | 412 | |||||
U.S., Canada and Latin America($M) | 371 | 387 | 361 | 327 | 334 | 323 | 288 | 298 | |||||
Combined Europe, Asia and other markets($M) | 154 | 143 | 128 | 128 | 122 | 119 | 123 | 114 | |||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2 | |||||||||||||
Global revenue($M) | 1,431 | 1,423 | 1,336 | 1,292 | 1,282 | 1,225 | 1,223 | 1,197 | 1,163 | ||||
U.S., Canada and Latin America($M) | 819 | 835 | 775 | 749 | 749 | 707 | 687 | 669 | |||||
Combined Europe, Asia and other markets($M) | 442 | 421 | 395 | 381 | 377 | 360 | 362 | 349 | |||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)3 | |||||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)3 | |||||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)3 | |||||||||||||
Global Sleep & Breathing Health Revenue ($M)($M)2 | 1,260 | 1,292 | 1,261 | 1,256 | 1,169 | 1,181 | 1,131 | 1,126 | 1,068 | 1,071 | 1,049 | 1,018 | |
Global Sleep & Breathing Health — Revenue Growth YoY (%)(%) | 8.0% | 9.0% | 11.0% | 12.0% | 10.0% | 10.0% | 8.0% | 11.0% | 11.0% | 9.0% | 7.0% | 11.0% | |
Global Sleep & Breathing Health — Constant Currency Growth YoY (%)(%) | 7.0% | 8.0% | 8.0% | 10.0% | 8.0% | 9.0% | 9.0% | 11.0% | 11.0% | 9.0% | 7.0% | 10.0% | |
Global Devices Revenue ($M)($M)5 | 720 | 750 | 736 | 726 | 680 | 694 | 676 | 669 | 626 | 635 | 638 | 606 | |
Global Devices — Revenue Growth YoY (%)(%) | 6.0% | 8.0% | 9.0% | 9.0% | 9.0% | 9.0% | 6.0% | 10.0% | 11.0% | 5.0% | 5.0% | 12.0% | |
Global Devices — Constant Currency Growth YoY (%)(%) | 6.0% | 7.0% | 6.0% | 7.0% | 7.0% | 8.0% | 7.0% | 11.0% | 10.0% | 6.0% | 5.0% | 11.0% | |
Global Devices — Share of Quarterly Consolidated Revenue (Legacy through FY2026Q3, %)(%) | 51.0% | 51.0% | 51.0% | 52.0% | 52.0% | 52.0% | 51.0% | 52.0% | 53.0% | 52.0% | |||
Americas Devices Revenue ($M)($M)3 | 436 | 459 | 448 | 448 | 413 | 433 | 423 | 415 | 385 | 406 | 399 | 371 | |
Americas Devices — Revenue Growth YoY (%)(%) | 6.0% | 6.0% | 6.0% | 8.0% | 8.0% | 7.0% | 6.0% | 12.0% | 11.0% | 5.0% | 7.0% | 7.0% | |
Americas Sleep Devices Revenue ($M)($M)1 | 436 | 452 | 436 | 438 | 405 | ||||||||
Americas Sleep Devices — Core Constant Currency Growth YoY (%)(%) | 6.0% | 8.0% | 7.0% | 10.0% | 9.0% | ||||||||
Americas Life Support Devices Revenue ($M)($M)1 | 0 | 7 | 11 | 10 | 9 | ||||||||
Americas Life Support Devices — Core Constant Currency Growth YoY (%)(%) | -94.0% | -45.0% | -29.0% | -41.0% | -27.0% | ||||||||
Rest of World Devices Revenue ($M)($M)4 | 284 | 291 | 288 | 278 | 267 | 261 | 254 | 255 | 241 | 229 | 239 | 235 | |
Rest of World Devices — Revenue Growth YoY (%)(%) | 6.0% | 12.0% | 14.0% | 9.0% | 11.0% | 14.0% | 6.0% | 9.0% | 10.0% | 6.0% | 1.0% | 19.0% | |
Rest of World Devices — Constant Currency Growth YoY (%)(%) | 6.0% | 9.0% | 6.0% | 5.0% | 7.0% | 10.0% | 9.0% | 9.0% | 9.0% | 8.0% | 1.0% | 16.0% | |
Rest of World Sleep Devices Revenue ($M)($M)1 | 280 | 281 | 276 | 266 | 250 | ||||||||
Rest of World Sleep Devices — Core Constant Currency Growth YoY (%)(%) | 13.0% | 13.0% | 9.0% | 6.0% | 6.0% | ||||||||
Rest of World Life Support Devices Revenue ($M)($M)1 | 3 | 10 | 12 | 12 | 17 | ||||||||
Rest of World Life Support Devices — Core Constant Currency Growth YoY (%)(%) | -79.0% | -38.0% | -30.0% | -15.0% | 9.0% | ||||||||
Global Masks and Other Revenue ($M)($M)5 | 540 | 542 | 525 | 530 | 489 | 487 | 454 | 456 | 442 | 436 | 411 | 412 | |
Global Masks and Other — Revenue Growth YoY (%)(%) | 10.0% | 11.0% | 15.0% | 16.0% | 11.0% | 12.0% | 11.0% | 11.0% | 11.0% | 14.0% | 10.0% | 10.0% | |
Global Masks and Other — Constant Currency Growth YoY (%)(%) | 10.0% | 10.0% | 12.0% | 14.0% | 10.0% | 11.0% | 12.0% | 11.0% | 11.0% | 15.0% | 10.0% | 9.0% | |
Global Masks and Other — Share of Quarterly Consolidated Revenue (Legacy through FY2026Q3, %)(%) | 37.0% | 37.0% | 37.0% | 36.0% | 35.0% | 36.0% | 36.0% | 36.0% | 34.0% | 35.0% | |||
Americas Masks and Other Revenue ($M)($M)1 | 397 | 394 | 371 | 387 | 361 | 359 | 327 | 335 | 323 | 321 | 288 | 298 | |
Americas Masks and Other — Revenue Growth YoY (%)(%) | 10.0% | 10.0% | 14.0% | 16.0% | 12.0% | 12.0% | 13.0% | 12.0% | 10.0% | 17.0% | 12.0% | 10.0% | |
Rest of World Masks and Other Revenue ($M)($M)2 | 143 | 148 | 154 | 143 | 128 | 128 | 128 | 122 | 119 | 115 | 123 | 114 | |
Rest of World Masks and Other — Revenue Growth YoY (%)(%) | 12.0% | 16.0% | 20.0% | 17.0% | 7.0% | 11.0% | 4.0% | 7.0% | 13.0% | 7.0% | 6.0% | 9.0% | |
Rest of World Masks and Other — Constant Currency Growth YoY (%)(%) | 11.0% | 12.0% | 10.0% | 8.0% | 4.0% | 7.0% | 7.0% | 7.0% | 11.0% | 9.0% | 6.0% | 4.0% | |
Americas Sleep & Breathing Health Total Revenue ($M)($M)2 | 833 | 853 | 819 | 835 | 775 | 792 | 749 | 749 | 707 | 727 | 688 | 669 | |
Americas Sleep & Breathing Health — Revenue Growth YoY (%)(%) | 8.0% | 8.0% | 9.0% | 11.0% | 10.0% | 9.0% | 9.0% | 12.0% | 11.0% | 10.0% | 9.0% | 9.0% | |
Americas Sleep & Breathing Health — Share of Quarterly Revenue (Legacy through FY2026Q3, %)(%) | 57.0% | 59.0% | 58.0% | 58.0% | 58.0% | 59.0% | 58.0% | 60.0% | 57.0% | 57.0% | |||
Rest of World Sleep & Breathing Health Total Revenue ($M)($M)3 | 426 | 439 | 442 | 421 | 395 | 389 | 381 | 377 | 360 | 344 | 362 | 349 | |
Rest of World Sleep & Breathing Health — Revenue Growth YoY (%)(%) | 8.0% | 13.0% | 16.0% | 12.0% | 10.0% | 13.0% | 5.0% | 8.0% | 11.0% | 7.0% | 3.0% | 16.0% | |
Rest of World Sleep & Breathing Health — Constant Currency Growth YoY (%)(%) | 8.0% | 10.0% | 7.0% | 6.0% | 6.0% | 9.0% | 8.0% | 8.0% | 10.0% | 8.0% | 3.0% | 12.0% | |
Rest of World Sleep & Breathing Health — Share of Quarterly Revenue (Legacy through FY2026Q3, %)(%) | 31.0% | 29.0% | 30.0% | 30.0% | 29.0% | 29.0% | 29.0% | 28.0% | 30.0% | 30.0% | |||
Residential Care Software (RCS) Revenue ($M)($M)3 | 155 | 172 | 171 | 167 | 166 | 167 | 161 | 157 | 157 | 152 | 148 | 145 | |
Residential Care Software — Revenue Growth YoY (%)(%) | -7.0% | 3.0% | 6.0% | 7.0% | 6.0% | 10.0% | 9.0% | 8.0% | 13.0% | 10.0% | 8.0% | 24.0% | |
Residential Care Software — Constant Currency Growth YoY (%)(%) | 5.0% | 2.0% | 4.0% | 5.0% | 5.0% | 9.0% | 10.0% | 8.0% | 12.0% | 10.0% | 8.0% | ||
Residential Care Software — Share of Quarterly Consolidated Revenue (Legacy through FY2026Q3, %)(%) | 12.0% | 12.0% | 12.0% | 12.0% | 13.0% | 12.0% | 13.0% | 12.0% | 13.0% | 13.0% | |||
Total Operating Segments Profit ($M)($M) | 614 | 582 | 634 | 622 | 585 | 575 | 548 | 538 | 509 | 484 | 495 | 451 | |
Total Operating Segments Cost of Sales ($M)($M)2 | 528 | 593 | 530 | 534 | 504 | 517 | 515 | 518 | 498 | ||||
Sleep & Breathing Health — Segment Cost of Sales ($M)($M)1 | 480 | 542 | 542 | 483 | 487 | 468 | 467 | 468 | 450 | 428 | 448 | 461 | |
Sleep & Breathing Health — Acquired Intangible Amortization in Cost of Sales (Legacy through FY2026Q4, $M)($M) | 2.01 | 2.01 | 1.42 | 1.42 | 3.02 | 1.18 | 1.23 | 1.21 | 1.22 | 1.05 | 1.32 | ||
Residential Care Software — Segment Cost of Sales ($M)($M)1 | 48.2 | 60.4 | 60.4 | 57.3 | 57.9 | 48.5 | 48.3 | 49.8 | 48.3 | 46.5 | 48 | 46.9 | |
Residential Care Software — Acquired Intangible Amortization in Cost of Sales (Legacy through FY2026Q4, $M)($M) | 6.29 | 6.29 | 6.39 | 6.40 | 6.34 | 6.26 | 6.40 | 6.46 | 6.77 | 6.76 | 6.93 | ||
Total Operating Segments Research & Development Expense ($M)($M)2 | 88.6 | 93.3 | 82.6 | 79.9 | 75.9 | 75.9 | 72.1 | 74.2 | 72.1 | ||||
Sleep & Breathing Health — Segment R&D Expense ($M)($M) | 65.9 | 66.7 | 56.4 | 54.1 | 50.9 | 51.1 | 47.2 | 50.1 | 47.9 | ||||
Residential Care Software — Segment R&D Expense ($M)($M) | 22.7 | 26.6 | 26.2 | 25.8 | 25 | 24.7 | 24.9 | 24.1 | 24.2 | ||||
Total Operating Segments SG&A Expense ($M)($M)2 | 185 | 196 | 185 | 187 | 171 | 180 | 156 | 153 | 146 | ||||
Sleep & Breathing Health — Segment SG&A Expense ($M)($M) | 155 | 160 | 150 | 148 | 135 | 142 | 122 | 119 | 109 | ||||
Residential Care Software — Segment SG&A Expense ($M)($M) | 29.8 | 35.8 | 35.6 | 39.5 | 36.3 | 38.4 | 34.7 | 33.7 | 36.6 | ||||
Sleep & Breathing Health — Segment Depreciation & Amortization ($M)($M)2 | 26.8 | 23 | 36.9 | 27.3 | 25 | 39.5 | 22.8 | 25.2 | 23 | 21.8 | 21.8 | 22 | |
Sleep & Breathing Health — Segment Goodwill ($M)($M)1 | 1,097 | 1,093 | 899 | 884 | 884 | 884 | 758 | 747 | 769 | 758 | 745 | 752 | |
Non-GAAP Gross Margin (%)(%)3 | 62.5% | 62.3% | 62.8% | 62.3% | 62.0% | 61.4% | 59.9% | 59.2% | 59.2% | 59.1% | 58.5% | 56.9% | |
GAAP Gross Margin (%)(%) | 61.5% | 58.8% | 62.2% | 61.8% | 61.5% | 60.8% | 59.3% | 58.6% | 58.6% | 58.5% | 57.9% | 55.6% | |
Non-GAAP Gross Profit ($M)($M) | 884 | 911 | 899 | 887 | 829 | 828 | 774 | 759 | 725 | 724 | 701 | 662 | |
Non-GAAP Cost of Sales (Legacy through FY2026Q4, $M)($M) | 552 | 533 | 536 | 507 | 520 | 518 | 523 | 500 | 500 | 496 | 501 | ||
Non-GAAP Income from Operations ($M)($M)3 | 506 | 515 | 525 | 517 | 482 | 476 | 445 | 436 | 406 | 401 | 394 | 366 | |
Non-GAAP Income from Operations — Growth YoY (%)(%) | 5.0% | 8.0% | 18.0% | 19.0% | 19.0% | 19.0% | 13.0% | 19.0% | 27.0% | 30.0% | 23.0% | 20.0% | |
GAAP Income from Operations — Growth YoY (%)(%) | 1.0% | -1.0% | 17.0% | 18.0% | 15.0% | 19.0% | 14.0% | 52.0% | 34.0% | 38.0% | 25.0% | -2.0% | |
Non-GAAP SG&A Expenses ($M)($M)6 | 276 | 291 | 280 | 259 | 265 | 245 | |||||||
Non-GAAP Net Income ($M)($M)3 | 418 | 428 | 417 | 412 | 375 | 375 | 349 | 358 | 325 | 306 | 314 | 277 | |
Non-GAAP Net Income — Growth YoY (%)(%) | 12.0% | 14.0% | 20.0% | 15.0% | 15.0% | 22.0% | 11.0% | 29.0% | 35.0% | 30.0% | 27.0% | 13.0% | |
GAAP Net Income — Growth YoY (%)(%) | 20.0% | 1.0% | 9.0% | 14.0% | 12.0% | 30.0% | 21.0% | 65.0% | 42.0% | 27.0% | 29.0% | -7.0% | |
Non-GAAP Diluted EPS ($)($)2 | 2.91 | 2.95 | 2.86 | 2.81 | 2.55 | 2.55 | 2.37 | 2.43 | 2.20 | 2.08 | 2.13 | 1.88 | |
Non-GAAP Diluted EPS — Growth YoY (%)(%) | 14.0% | 16.0% | 21.0% | 16.0% | 16.0% | 23.0% | 11.0% | 29.0% | 34.0% | 30.0% | 27.0% | 13.0% | |
GAAP Diluted EPS — Growth YoY (%)(%) | 23.0% | 2.0% | 10.0% | 15.0% | 12.0% | 30.0% | 22.0% | 65.0% | 42.0% | 27.0% | 29.0% | -7.0% | |
Free Cash Flow — Published Non-GAAP ($M)1 | |||||||||||||
Unused Revolving Credit Facility Borrowing Capacity ($M)($M) | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 | 1,470 | 1,175 | 955 | |
Cash & Cash Equivalents Held Within the United States ($M)($M)1 | 278 | 732 | 944 | 795 | 697 | 555 | 409 | 206 | 136 | 51.2 | 55.8 | 38.2 | |
Cash & Cash Equivalents Held by Non-U.S. Subsidiaries ($M)($M) | 733 | 737 | 717 | 623 | 687 | 655 | 523 | 316 | 290 | 187 | 182 | 172 | |
Common Stock Repurchased (shares)3 | 3,643,502 | 971,964 | 673,418 | 703,702 | 523,212 | 418,734 | 314,100 | 306,850 | 221,996 | 231,645 | 260,714 | 335,474 | |
Weighted-Average Price Paid per Repurchased Share ($)($) | 232 | 206 | 260 | 249 | 286 | 239 | 239 | 244 | 225 | 216 | 192 | 149 | |
Cumulative Shares Repurchased Since Program Inception (shares) | 50,441,545 | 46,798,043 | 45,826,079 | 45,152,661 | 44,448,959 | 43,925,747 | 43,507,013 | 43,192,913 | 42,886,063 | 42,664,067 | 42,432,422 | 42,171,708 | |
Remaining Shares Authorized for Repurchase Under Board Program (shares) | 7,917,970 | 8,889,934 | 9,563,352 | 10,267,054 | 10,790,266 | 11,209,000 | 11,523,100 | 11,829,950 | 12,051,946 | 12,283,591 | 12,544,305 | ||
Total Inventories, Net ($M)($M)4 | 1,021 | 946 | 912 | 922 | 946 | 928 | 863 | 882 | 918 | 822 | 830 | 933 | |
Inventories — Finished Goods, Net ($M)($M) | 619 | 547 | 559 | 546 | 581 | 558 | 516 | 515 | 542 | 464 | 421 | 463 | |
Inventories — Raw Materials, Net ($M)($M) | 398 | 396 | 351 | 375 | 363 | 367 | 343 | 365 | 373 | 356 | 407 | 467 | |
Inventories — Work in Process, Net ($M)($M) | 4.10 | 2.60 | 2 | 1 | 2 | 2.50 | 3.30 | 2.60 | 2.50 | 2.70 | 1.80 | 2.90 | |
Prepaid Inventory ($M)($M) | 31.8 | 27.2 | 25.1 | 23.2 | 25.7 | 48.2 | 66.2 | 104 | 146 | 172 | 197 | 197 | |
Customer Contract Liabilities / Deferred Revenue — Current ($M)($M)3 | 172 | 163 | 179 | 176 | 168 | 166 | 160 | 157 | 157 | 153 | 151 | 149 | |
Customer Contract Liabilities / Deferred Revenue — Noncurrent ($M)($M) | 174 | 171 | 163 | 160 | 159 | 157 | 151 | 147 | 145 | 137 | 132 | 127 | |
Customer Contract Assets — Current ($M)($M) | 51.9 | 48.7 | 47.1 | 61.4 | 51.1 | 51.2 | 51.6 | 47 | 43.8 | 38.2 | 37.9 | 34.6 | |
Customer Contract Assets — Noncurrent ($M)($M) | 13.5 | 14.1 | 14.2 | 14.4 | 14.3 | 14.6 | 14.1 | 15 | 15.9 | 18.4 | 11.1 | 10.8 | |
Finite-Lived Intangible Assets, Net ($M)($M)3 | 443 | 453 | 425 | 430 | 447 | 465 | 430 | 438 | 479 | 486 | 501 | 528 | |
Property, Plant & Equipment, Gross ($M)($M) | 1,360 | 1,333 | 1,346 | 1,312 | 1,287 | 1,256 | 1,233 | 1,214 | 1,325 | 1,275 | 1,257 | 1,266 | |
Operating Lease Right-of-Use Assets ($M)($M)3 | 197 | 153 | 162 | 166 | 162 | 168 | 153 | 151 | 157 | 151 | 147 | 154 | |
Product Warranty Accrual — Current ($M)1 | |||||||||||||
FDA 510(k) Premarket Clearances — ResMed2 | 1 | 3 | 1 | 1 | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 1 | |
FDA 510(k) Premarket Clearances — U.S. MedTech Industry Total | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
FDA Premarket Approvals (PMA & Supplements) — U.S. MedTech Industry Total | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
FDA Medical Device Recall Events — ResMed1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | |
FDA Device Enforcement Reports — ResMed | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | |
FDA MAUDE Adverse Event Reports — ResMed Total4 | 338 | 215 | 220 | 328 | 270 | 166 | 204 | 252 | 271 | 229 | 248 | 332 | |
ClinicalTrials.gov Newly Started Studies — ResMed | 2 | 3 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | ||||
U.S. Federal Prime Contract Obligations — ResMed Total ($M)($M) | 0.00 | 0.04 | 0.16 | 0.03 | 0.06 | 0.03 | 0.20 | 0.64 | 0.06 | 0.66 | 0.24 | 0.66 | |
U.S. PPI: Electromedical & Electrotherapeutic Apparatus Mfg (Index)(×)4 | 92.80 | 92.10 | 92.00 | 91.60 | 90.90 | 90.30 | 90.10 | 89.50 | 89.30 | 88.40 | 88.40 | 87.80 | |
Consolidated Net Revenue ($M)($M)10 | 1,415 | 1,464 | 1,431 | 1,423 | 1,336 | 1,348 | 1,292 | 1,282 | 1,225 | 1,223 | 1,197 | 1,163 | |
Total Assets ($M)($M)15 | 8,212 | 8,966 | 8,784 | 8,503 | 8,308 | 8,174 | 7,567 | 7,141 | 7,222 | 6,872 | 6,815 | 6,905 | |
Net Cash Provided by Operating Activities ($M)($M)8 | 422 | 455 | 554 | 340 | 457 | 539 | 579 | 309 | 326 | 440 | 402 | 273 | |
6 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Sleep & Breathing Health Disaggregation (Group 1): Combines Form 10-K/10-Q XBRL disaggregation and Form 8-K Revenue by Product and Region tables across 25 consecutive quarters (Q1 FY2021–Q1 FY2027) and 8 fiscal years (FY2019–FY2026). Starting Q1 FY2027, ResMed further disaggregated Devices into Sleep Devices (CPAP, APAP, and bilevel devices) and Life Support Devices (ventilators) with restated quarterly figures for Q1–Q4 FY2026 across the Americas and Rest of World.
- Residential Care Software & Portfolio Transformation (Group 2): Tracks Residential Care Software (formerly Software-as-a-Service) revenue, constant-currency growth, business mix, segment operating profit, segment cost of sales, segment R&D, segment SG&A, D&A, and goodwill. On September 1, 2026 (Q1 FY2027), ResMed completed the divestiture of its MatrixCare skilled nursing software business for $490 million ($450.8 million net cash proceeds; $62.2 million pre-tax gain), retaining Brightree (U.S. HME/home health SaaS) and MEDIFOX DAN (German out-of-hospital software).
- Consolidation Structure Assessment: ResMed Inc. files consolidated U.S. GAAP financial statements in Form 10-K and Form 10-Q without parent-only standalone operational financial statements; accordingly, consolidated minus parent-only subtraction is not applicable. Subsidiary footprint by country is tracked via Form 10-K Exhibit 21.1 and Note 17 geographic disclosures in Group 6.
- Period Splitting & Derived Figures: Quarterly fourth-quarter (Q4) segment and product revenue figures not separately tabulated in Form 10-K are derived by subtracting nine-month cumulative totals (Form 10-Q for Q3) from full-year totals (Form 10-K), and Q2–Q4 cash flow figures are derived from cumulative year-to-date cash flow statements. No self-calculated ratios, margins, shares, or growth rates are included.
Không hiện vì thiếu các kỳ gần đây (10)
- 100% Cloud-Connectable Devices in Market ('>31.5M', '>34.5M', '>35.0M', '>37M') — Disclosed solely with lower-bound '>' qualifiers across quarterly presentations and sustainability reports.
- Patients in AirView Remote Monitoring Ecosystem ('>30M', '>33M', '>35M', '36M+') — Disclosed solely with lower-bound '>' or '+' qualifiers in investor presentations.
- Patients Registered in myAir Patient Engagement App ('>10M', '>11.0M', '>11.5M', '>12M') — Disclosed solely with lower-bound '>' qualifiers.
- Cumulative Nights of Sleep & Respiratory Medical Data in Cloud ('>21.5B', '>23.5B', '24.5B+', '25.5B+') — Disclosed solely with lower-bound '>' or '+' qualifiers.
- Lives Improved in Out-of-Hospital Care ('>149M', '>154M', '>165M', '169M+') and Countries Served ('140+') — Disclosed solely as lower-bound figures.
- Global Sleep Devices & Global Life Support Devices Standalone Revenue ($716M / $4M in Q1 FY2027; $655M / $25M in Q1 FY2026) — Global totals disclosed for only 2 quarters (Q1 FY2026 and Q1 FY2027) without Q2–Q4 FY2026 global subtotals, whereas Americas and Rest of World Sleep Devices and Life Support Devices have all 5 consecutive quarters (Q1 FY2026–Q1 FY2027) plus FY2026 full year and are included in Group 1.
- Americas Masks and Other & Total Americas Sleep and Breathing Health Core Constant Currency Growth (10% and 7% in Q1 FY2027) — Disclosed for only 1 quarter (Q1 FY2027) following the Noctrix acquisition adjustment; prior Form 8-K tables reported only GAAP YoY growth for the Americas.
- EU Public Country-by-Country Report (CbCR) Country Breakdown (Germany $343.4M / 1,306 employees, France $303.8M / 392 employees, Netherlands $785.1M, Ireland $181.3M, Italy $53.1M, Finland $44.1M) — Published for a single fiscal year (FY2025) under EU Directive 2021/2101 (<2 consecutive years).
- Tier I Direct Supplier Code of Conduct & Environmental/Safety Assessment Rate ('95+%' in FY2023–FY2026 Sustainability Reports) — Disclosed solely as a lower-bound percentage ('95+%').
- Total Recordable Injury Frequency Rate (TRIFR: 4.19 in FY2021, 3.31 in FY2022, 3.09 in FY2023) and Lost Time Injury Frequency Rate (LTIFR: 1.71, 1.89, 1.98) — Discontinued in the FY2025 and FY2026 Sustainability Data Tables.
Dữ liệu cập nhật 2026-11-08.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Sleep & Breathing Health Franchise — Product & Geographic Revenue Drivers
Residential Care Software (Out-of-Hospital SaaS) & Segment Cost Structure
- Residential Care Software (RCS) Revenue ($M) ($M)25 kỳ
- Total Operating Segments Profit ($M) ($M)25 kỳ
- Total Operating Segments Cost of Sales ($M) ($M)9 kỳ
- Total Operating Segments Research & Development Expense ($M) ($M)9 kỳ
- Total Operating Segments SG&A Expense ($M) ($M)9 kỳ
- Sleep & Breathing Health — Segment Depreciation & Amortization ($M) ($M)25 kỳ
- Sleep & Breathing Health — Segment Goodwill ($M) ($M)23 kỳ
Non-GAAP Profitability, Liquidity, Share Repurchases & Capital Allocation
Inventory by Stage, Customer Contract Balances, Intangible Classes & Leases
- Total Inventories, Net ($M) ($M)23 kỳ
- Customer Contract Liabilities / Deferred Revenue — Current ($M) ($M)23 kỳ
- Finite-Lived Intangible Assets, Net ($M) ($M)23 kỳ
- Property, Plant & Equipment, Gross ($M) ($M)23 kỳ
- Operating Lease Right-of-Use Assets ($M) ($M)23 kỳ
- Product Warranty Accrual — Current ($M) ($M)7 kỳ
Workforce, Patent Portfolio, Manufacturing Facilities, Supply Chain & ESG
Subsidiaries & Country-Level Geographic Disclosures
External MedTech Regulatory, Clinical Trials, Federal Procurement & Sector Benchmarks
- FDA 510(k) Premarket Clearances — ResMed153 kỳ
- FDA Medical Device Recall Events — ResMed153 kỳ
- FDA MAUDE Adverse Event Reports — ResMed Total153 kỳ
- ClinicalTrials.gov Newly Started Studies — ResMed33 kỳ
- U.S. Federal Prime Contract Obligations — ResMed Total ($M) ($M)99 kỳ
- U.S. PPI: Electromedical & Electrotherapeutic Apparatus Mfg (Index) (×)129 kỳ
Consolidated Financial Statements & Segment Context
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của ResMed
- ResMed SEC Filing (0000943819-26-000089) ↗
- ResMed SEC Filing (0000943819-26-000047) ↗
- U.S. FDA openFDA Device Clearances, PMA, Recalls & MAUDE ↗
- ResMed SEC Filing (0001193125-26-337962) ↗
- ResMed SEC Filing (0001193125-26-437783) ↗
- USAspending.gov Federal Prime Contract Awards — ResMed ↗
- Federal Reserve Economic Data — PCU334510334510 ↗
- NIH ClinicalTrials.gov Registry — ResMed ↗
- ResMed SEC Filing (0000943819-23-000011) ↗
- ResMed SEC Filing (0000943819-26-000080) ↗
- ResMed SEC Filing (0001193125-26-239446) ↗
- ResMed 2026 Sustainability Report (FY2026) (2026-11-04) ↗
See a number that looks wrong?